Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Medifast Inc (MED)
NYSE:MED
Holding MED?
Track your performance easily
Earnings Data
Report Date
Feb 25, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.16Last Year’s EPS
$1.09Same Quarter Last Year
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 04, 2024
|% Change Since: -10.05%
|Next Earnings Date:Feb 25, 2025
Earnings Call Sentiment|Neutral
Medifast is facing significant challenges due to the market shift towards GLP-1 medications, resulting in decreased revenue and active coaches. However, the company is actively adapting by training coaches, developing new products tailored to the current market, and maintaining a strong cash position to support its transformation efforts.Company Guidance
During the Medifast Q3 2024 earnings call, the company provided guidance for the fourth quarter, anticipating revenue between $100 million and $120 million, reflecting a decrease in active earning OPTAVIA coaches due to competition from GLP-1 medications. The projected loss per share is expected to range from $0.10 to $0.65. The company plans to spend $7 million on marketing in the fourth quarter, aiming to optimize customer acquisition efforts amidst challenges in the competitive landscape. Additionally, Medifast is preparing to launch new products under the OPTAVIA ASCEND brand, specifically designed to support individuals using GLP-1 medications, with a full rollout expected in early 2025. The company's strategic initiatives are supported by a strong balance sheet, with $170 million in cash and no interest-bearing debt.GLP-1 Medication Integration
Medifast has trained 95% of coach leaders to support clients using GLP-1 medications, with 40% of active coaches now supporting at least one client on these medications.
New Product Development
The company is launching a new program in 2025 with products under the OPTAVIA ASCEND brand, specifically designed for individuals on GLP-1 medications and those transitioning off them.
Strong Cash Position
Medifast ended the quarter with $170 million in cash, cash equivalents, and investments, with no interest-bearing debt.
---
MED Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MED Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 04, 2024 | $18.81 | $20.40 | +8.45% |
| Aug 05, 2024 | $20.86 | $20.27 | -2.83% |
| Apr 29, 2024 | $35.51 | $27.53 | -22.47% |
| Feb 20, 2024 | $48.93 | $40.38 | -17.47% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Medifast Inc (MED) report earnings?
Medifast Inc (MED) is schdueled to report earning on Feb 25, 2025, TBA Not Confirmed.
What is Medifast Inc (MED) earnings time?
Medifast Inc (MED) earnings time is at Feb 25, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MED EPS forecast?
MED EPS forecast for the fiscal quarter 2024 (Q4) is -$0.16.
---